SCHEMBL18285368

SCHEMBL18285368

CCC(C)(C)NC(=O)c1cc(-c2ccc(Cl)cc2)cc(-n2ccnc2CO)c1

nearest known ligand 0.38

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 4/20 0.38
CNR1 P21554 3/20 0.38
ANO1 Q5XXA6 3/20 0.38
L3MBTL1 Q9Y468 1/20 0.37
MAPT P10636 1/20 0.36
PDE4A P27815 1/20 0.36
PDE4B Q07343 1/20 0.36
PDE4C Q08493 1/20 0.36
PDE4D Q08499 1/20 0.36
GABRA5 P31644 2/20 0.35
SCN2A Q99250 1/20 0.33
SCN10A Q9Y5Y9 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18285329 0.91 CNR1 (0.41) CNR2CNR1ANO1MAPTPDE4A
SCHEMBL18285302 0.89 CNR1 (0.32) CNR2CNR1ANO1L3MBTL1MAPT
SCHEMBL18285318 0.87 ANO1 (0.39) CNR2CNR1ANO1L3MBTL1MAPT
SCHEMBL18285369 0.85 PDE4B (0.38) CNR2CNR1ANO1L3MBTL1PDE4A
SCHEMBL18285311 0.85 MAPT (0.42) CNR1ANO1MAPTPDE4APDE4B
SCHEMBL18285334 0.84 ANO1 (0.38) CNR2CNR1ANO1L3MBTL1
SCHEMBL18285357 0.82 MAPT (0.40) CNR1ANO1MAPTPDE4APDE4B
SCHEMBL18285317 0.81 CNR2 (0.46) CNR2CNR1ANO1GABRA5
SCHEMBL18285363 0.81 PDE4B (0.35) CNR2CNR1ANO1L3MBTL1PDE4A
SCHEMBL18285307 0.80 CNR2 (0.42) CNR2CNR1ANO1PDE4APDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107531642-B Imidazole derivatives 豪夫迈·罗氏有限公司 2021-06-22 CN claimed
EP-3303299-B1 IMIDAZOLE DERIVATIVES HOFFMANN LA ROCHE (CH) 2019-04-24 EP claimed
EP-3303299-A1 IMIDAZOLE DERIVATIVES H. Hoffnabb-La Roche Ag (CH) 2018-04-11 EP claimed
WO-2016193235-A1 IMIDAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2016-12-08 WO claimed
CN-107531642-B Imidazole derivatives 豪夫迈·罗氏有限公司 2021-06-22 CN disclosed
EP-3303299-B1 IMIDAZOLE DERIVATIVES HOFFMANN LA ROCHE (CH) 2019-04-24 EP disclosed
US-10029989-B2 Imidazole derivatives HOFFMANN-LA ROCHE INC. (US) 2018-07-24 US disclosed
US-10029989-B2 Imidazole derivatives HOFFMANN-LA ROCHE INC. (US) 2018-07-24 US disclosed
US-20180118692-A1 IMIDAZOLE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2018-05-03 US disclosed
US-20180118692-A1 IMIDAZOLE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2018-05-03 US disclosed
EP-3303299-A1 IMIDAZOLE DERIVATIVES H. Hoffnabb-La Roche Ag (CH) 2018-04-11 EP disclosed
WO-2016193235-A1 IMIDAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2016-12-08 WO disclosed
WO-2016193235-A1 IMIDAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2016-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180118692-A1 IMIDAZOLE DERIVATIVES DRD3, GABRR3, DRD4 CNR2 590/4885CNR1 214/4885ANO1 1134/4885
US-10029989-B2 Imidazole derivatives DRD3, GABRR3, DRD4 CNR2 590/4885CNR1 214/4885ANO1 1134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.